by Karen O'Hanlon Cohrt | Sep 24, 2024 | Citation Alerts
Tempo-iOligo™was cited in Nature in a major infectious disease study that offers the first explanation as to why herpes simplex virus 1 (HSV-1) infection in the brain is very rare, despite the fact that most of us have been infected with the virus. The study used...
by Allison Kennedy | May 10, 2023 | Citation Alerts
Tempo-iMG™ was cited in cell.com in a study that investigated HIV-1 integration in the unexplored microglia reservoir that gives rise to continued HIV replication in infected cells. Scientists used Tempo-iMG™ human iPSC-derived microglia to determine that CTCF, an...
by Allison Kennedy | Feb 13, 2023 | Citation Alerts
Tempo-iKidneyPod™ was mentioned in springer.com in a review article that summarized various investigative methods and applications of microfluidic chips, specifically to examine how SARS-CoV-2 causes acute kidney injury (AKI). Tempo-iKidneyPod™ is composed of human...
by Allison Kennedy | Dec 16, 2022 | Citation Alerts
Tempo-iMG™ and Tempo-iOligo™ were cited by scientists in a nature.com study where they built a 3D in vitro organoid model of the blood brain barrier (BBB). They chose to build their BBB model based on a composition of multiple neural and glial cell types. By utilizing...
by Allison Kennedy | Oct 10, 2022 | Citation Alerts
Tempo-iMG™, human iPSC-derived microglia, was used in a follow-up study cited in plos.org. This study expanded on a previous discovery showing that healthy microglia were able to silence HIV. Citation Summary In the current study, scientists from Case Western Reserve...
by Allison Kennedy | Oct 9, 2022 | Citation Alerts
Tempo-iMG™, Tempo-iCort™, Tempo-iDopaNer™, and Tempo-iMotorNer™ were utilized in a study cited in plos.org that examined the cross-talking relationship between microglia and neurons. It was critical that the researchers deployed Tempo’s iPSC-derivative cell types to...
